School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

Voyager Therapeutics, Inc. VYGR

Healthcare · Biotechnology

$2.45last close 2026-10-09 · market cap $150.96M · delayed data

Trailing returns

1M-24.62%
3M-33.42%
6M-38.13%
1Y-52.43%
5Y-55.86%

Basis: Adjusted daily closes.

What it does

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease.

Open VYGR in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies